Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00371709 · ClinicalTrials.gov registry record · Phase 3
TAXUS ATLAS: TAXUS Liberté™-SR Stent for the Treatment of de Novo Coronary Artery Lesions
A Phase 3 study, sponsored by Boston Scientific Corporation.
- Completed
- Registry status
- Phase 3
- Development phase
- 871
- Enrollment target
NCT00371709: Completed Phase 3 study, sponsored by Boston Scientific Corporation.
NCT00371709 is a Phase 3 study that has completed, run by Boston Scientific Corporation. The registered enrollment target is 871 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (13% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00371709, a Phase 3 study, has completed, sponsored by Boston Scientific Corporation.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 871 participants
- Enrollment target
Study Summary
TAXUS ATLAS is a global, multi-center, single-arm, non-inferiority trial comparing results from patients treated with the TAXUS Liberté stent to an historical TAXUS Express control. The control group is a case-matched, blended population of TAXUS Express patients from the TAXUS IV and TAXUS V de novo clinical trials. The objective of the study is to evaluate clinical outcomes of TAXUS Liberté-SR stent in de novo lesions and to assess the non-inferiority of TAXUS Liberté versus TAXUS Express. The TAXUS Liberté-SR stent is hypothesized to have comparable safety and efficacy to the TAXUS Express stent.
Interventions
- DEVICE TAXUS Liberté-SR
- DEVICE TAXUS™ Express
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 871 participants |
| Start Date | 2004-08 |
| Est. Completion | 2010-03 |
| Phase | Phase 3 |
What the finished NCT00371709 record still lists
NCT00371709 is an interventional study that assigns participants to a tested intervention. The registered 871 participants enrollment target is mid-sized for trials with a published cap, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (13% higher).
The record links to 0 conditions, and to 2 interventions - of which TAXUS Liberté-SR is the first listed.
NCT00371709 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00371709 about?
NCT00371709 is a clinical study titled "TAXUS ATLAS: TAXUS Liberté™-SR Stent for the Treatment of de Novo Coronary Artery Lesions". TAXUS ATLAS is a global, multi-center, single-arm, non-inferiority trial comparing results from patients treated with the TAXUS Liberté stent to an historical TAXUS Express control. The control group is a case-matched, blended population of TAXUS Express patients from the TAXUS IV and TAXUS V de nov...
What is the current status of trial NCT00371709?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 871 participants. The study started on 2004-08. Estimated completion is 2010-03.
What interventions are being tested in trial NCT00371709?
The interventions under investigation include: TAXUS Liberté-SR (DEVICE), TAXUS™ Express (DEVICE).
Who is sponsoring clinical trial NCT00371709?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00371709's enrollment target sits among peer trials
871 373rd of 2000 higher than 1,628 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04097145 · 870 participants · NA
Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial
- NCT06822790 · 869 participants · Phase 3
Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia
- NCT06077760 · 868 participants · Phase 3
A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)
- NCT04933552 · 867 participants
Post-Authorization Safety Study for Assessment of Pregnancy Outcomes in Patients Treated With Mayzent
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia